of PAD. Ankle brachial pressure index measurement by oscillometry cannot completely substitute the Doppler method, especially in those patients with crural artery occlusive disease. 12 Other diagnostic tests for PAD have also been described, such as angiography using a variety of radiographic techniques (eg, digital subtraction, 13, 14 computed tomography, [13] [14] [15] or magnetic resonance 13, 16, 17 angiography), optical devices based on the photoplethysmograph method, 18, 19 magnetic resonance spectroscopy, 17 and pulse oximetry. 20 This Editorial briefly discusses the importance of conservative (nonsurgical/noninterventional) measures in the management of PAD.
Smoking
Smoking is the most powerful predictor [21] [22] [23] and is independently associated with the development of PAD 3, 5, [23] [24] [25] ; an almost 4-fold increased risk of PAD due to smoking has been reported (odds ratio [OR] per year, 3.83; 95% CI, 2.49-5.91). 3, 5, [23] [24] [25] Additionally, a dose-dependent association between smoking and the severity of PAD has been supported. 25 Both active 22 and passive 26 cigarette smoking impair flowmediated endothelium-dependent peripheral arterial vasodilatation (arterial stiffness). Therefore, smoking cessation is essential to prevent disease progression, as well as to decrease clinical deterioration (ie, walking distance) and amputation rates. [23] [24] [25] 
Exercise
Adoption of a structured exercise program can improve ischemic symptoms, walking distance, and quality of life in patients with PAD. [27] [28] [29] [30] [31] According to P eripheral arterial disease (PAD) affects a considerable percentage of the elderly population. [1] [2] [3] According to the National Health and Nutrition Examination Survey, 18.6% of the adult US population who were aged ≥40 years has lower extremity disease, including PAD and peripheral insensate neuropathy. 4, 5 A large (n = 264,570 patients) international (16 countries) survey of middle-aged adults (age, 54-64 years) reported an 8% prevalence of PAD. 6 The prevalence of PAD increases with age: 7.0% (95% confidence interval [CI], 5.6%-8.4%), 12.5% (95% CI, 10.4%-14.6%), and 23.2% (95% CI, 19.8%-26.7%) for those who were aged 60-69, 70-79, and >80 years, respectively. 5 Out of these, around twothirds are asymptomatic. 4 Peripheral arterial disease often evades diagnosis; a cross-sectional study among primary care physicians revealed that unrecognized asymptomatic PAD can be commonly detect the primary care setting among patients who are not known to have vascular disease. 7 In addition, a high prevalence of unrecognized PAD in patients hospitalized for nonvascular diseases has been reported. 8 As atherosclerosis is a systemic process, PAD often coexists with vascular disease in other arterial beds (eg, the coronary or cerebrovascular systems). 9,10 Among individuals with asymptomatic PAD, approximately 5% to 10% develop symptoms in the lower extremities over the next 5 years. 11 The ankle brachial pressure index measured by Doppler ultrasound is traditionally used for the diagnosis the results of a meta-analysis, exercise is more effective than either antiplatelet therapy or angioplasty for improving walking time, but it does not differ significantly from surgery. 32 Physical activity (eg, regular walking) is an independent predictor of all-cause mortality in patients with PAD. 33, 34 The optimal exercise program involves progressive walking to almost maximal pain intensity over >6 months. 32
Management of Dyslipidemia
Aggressive pharmacologic management of lipid abnormalities in patients with PAD (eg, with statins) is crucial. [35] [36] [37] [38] Achieving the National Cholesterol Education Program Adult Treatment Panel III guidelines for low-density lipoprotein cholesterol levels (70 mg/dL, 1.80 mmol/L) not only reduces the atherosclerosis burden in these patients (thus decreasing disease progression) but also reduces cardiovascular events, morbidity, and mortality rates. [35] [36] [37] [38] Statin treatment in these patients not only improves renal function 39, 40 but also decreases the progression of carotid atherosclerosis. 41 Furthermore, statins probably lower perioperative morbidity and mortality should PAD patients undergo surgery. 42, 43 Despite these multiple beneficial effects, there is evidence that the diagnosis and treatment of dyslipidemia in patients with PAD are suboptimal. 44, 45 
Antiplatelet Therapy
Patients with PAD have increased platelet activation. 46, 47 Antiplatelet agents also reduce vascular events and vascular death in these patients. 48 A collaborative meta-analysis included 287 studies (n = 135,000 patients) of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. 49 Antiplatelet therapy was associated with a 23% reduction in serious vascular events in the subset of >9000 patients with PAD. 49 A post hoc analysis of the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events study showed that clopidogrel is more effective than aspirin for the reduction of myocardial infarction, ischemic stroke, and vascular death in patients with PAD. 50 Cilostazol is a phosphodiesterase type III inhibitor that decreases platelet aggregation. 28 A recent systematic review of 7 randomized controlled trials comparing cilostazol with placebo showed that treatment with 100 or 50 mg of cilostazol twice daily improved initial claudication distance. 28
Antihypertensive Therapy
Patients with PAD should have tight blood pressure control to reduce disease progression and cardiovascular events. After a mean follow-up interval of 5 years, assignment to 10 mg/d of ramipril was associated with a relative risk reduction of approximately 25% (95% CI, 14%-37%) of subsequent stroke, myocardial infarction, and vascular death compared with placebo among 4051 patients with PAD enrolled in the Heart Outcomes Prevention Evaluation study. 51 The Appropriate Blood pressure Control in Diabetes study also demonstrated the superiority of intensive over moderate blood pressure control. 52 Patients receiving intensive antihypertensive treatment had significantly few cardiovascular events compared with those patients on moderate blood pressure lowering treatment (3 vs 12 events or 13.6% vs 38.7%, respectively, P = .046). 52 Therefore, the results of these studies demonstrate that intensive blood pressure control in patients with PAD should be reinforced.
Glycemic Control
Individuals with diabetes mellitus are at increased risk not only of developing intermittent claudication and PAD but also of needing amputation. 53 The UK Prospective Diabetes Study Group showed that each 1% increase in glycosylated hemoglobin levels is associated with a 28% increased risk of incident PAD 54 and with a 28% increased risk of death, 55 independent of other variables, such as blood pressure, serum cholesterol, age or smoking status (P < .002). Thus, aggressive control of hyperglycemia in diabetes mellitus is essential to prevent disease progression and reduce cardiovascular risk.
Possible Future Approaches: Therapeutic Angiogenesis
The process of angiogenesis by administration of vascular growth factors is a possible future treatment alternative for patients with PAD. [56] [57] [58] So far, only preliminary evidence based largely on animal and tissue studies are available. [56] [57] [58] Future trials may provide more conclusive results that could help establish the role of angiogenesis in the treatment of PAD.
Conclusions
Conservative measures (smoking cessation, adoption of a regular exercise program, management of dyslipidemia, strict glycemic control, antihypertensive, and antiplatelet treatment) comprise the mainstay of the therapeutic approach of patients with PAD. Failure to meet the established guidelines for blood pressure, blood glucose, and lipid levels is associated with considerable morbidity and mortality, as well as a declining course of the disease. Optimal management of the risk factors is essential to achieve the best possible outcome for patients with PAD. 
